Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
ConclusionThis is the largest series of patients with pre-existing AD and treatment with ipilimumab reported. Flares of pre-existing AD were observed but manageable. Response rates and occurrence of new irAEs were comparable to previous trials. Thus, in this patient subgroup, ipilimumab can be a treatment option after a thorough discussion of pros and cons and taking severity and activity of the preexisting AD into account.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Autoimmune Disease | Brain | Cancer | Cancer & Oncology | Dermatology | Germany Health | Immunotherapy | Melanoma | Neurology | Rheumatology | Skin | Skin Cancer | Yervoy